Empagliflozin Ameliorates Angiotensin II-Induced Left Ventricular Diastolic Dysfunction by Suppressing EndoMT via PI3K/AKT/eNOS Signaling
{{output}}
Background: The SGLT2 inhibitor empagliflozin (EMPA) has been found to reduce the combined risk of cardiovascular death or hospitalization for heart failure in patients with or without reduced left ventricular ejection fraction, ... ...
